98%
921
2 minutes
20
Purpose: To compare prospective identification of adverse drug reaction (ADR)-related hospital admissions in the elderly with administrative coding using the International Classification of Diseases 10 Revision Australian Modification (ICD-10-AM) coding system.
Methods: We linked the records of 768 enrolled patients from an earlier study, where clinical pharmacists identified ADRs using prospective data collection, to hospital administrative data. We identified patients in the study whose admissions were coded as ADRs using ICD-10-AM codes. We then compared the prevalence and characteristics of ADR-related hospital admissions identified by the two approaches.
Results: According to ICD-10-AM coding, 2.7% of patients were admitted due to ADRs, while 15.0% of patients were deemed to have been admitted due to ADRs based on prospective identification by clinical pharmacists. Most (85.7%) patients coded as having an ADR-related hospital admission were also identified as such prospectively. Hematological (23.1%) and metabolic reactions (23.1%) were frequent causes of ADRs identified by coding, whereas cardiovascular ADRs (27.8%) were more common causes of ADRs identified prospectively by pharmacists. Antidepressants (16.7%) and cardiac glycosides (16.7%) were the most commonly implicated drug groups in ADRs identified by coding, whereas diuretics (28.8%) and renin-angiotensin system inhibitors (17.0%) were frequently implicated as causes of ADRs identified prospectively by pharmacists.
Conclusions: Reliance on administrative coding potentially underestimates the extent of the problem of ADRs as a cause of hospitalization in the elderly, and more detailed prospective analysis of admissions provides additional targets for strategies to prevent ADRs. The types of ADRs identified also differ between the two approaches.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1002/pds.4667 | DOI Listing |
PLoS One
September 2025
Discipline of Clinical Pharmacy, School of Pharmaceutical Sciences, University Sains Malaysia, Penang, Malaysia.
Background: Ensuring the safety of medications is a significant public health priority, with developed countries implementing robust pharmacovigilance programs. Despite this, healthcare providers continue to underreport adverse drug reactions (ADRs). This study aims to explore the existing pharmacovigilance system and procedure followed for ADR reporting in selected Dubai hospitals.
View Article and Find Full Text PDFSubst Use Addctn J
September 2025
Brain Boutique, Seoul, Korea.
Background: Misuse of anabolic-androgenic steroids (AAS), especially through "stacking" multiple substances, poses significant health risks. This study leverages data from the FDA's Adverse Event Reporting System (FAERS) to assess these risks and identify factors predicting severe outcomes.
Methods: We analyzed 286 FAERS reports of intentional AAS misuse.
J Pharmacol Toxicol Methods
September 2025
Department of Pharmacology, Faculty of Pharmacy, Kabul University, 1006 Kabul, Afghanistan.
Polypharmacy during tuberculosis (TB) treatment, particularly in patients with comorbidities such as diabetes mellitus (DM), significantly increases the risk of adverse drug reactions (ADRs) due to complex drug-drug interactions (DDIs). Existing computational methods primarily focus on pairwise drug interactions, often failing to capture the multifactorial nature of ADRs in polypharmacy contexts. To address this gap, we developed PolyCheck, a hybrid predictive model that integrates network-based and rule-based methods to identify potential ADRs arising from multi-drug regimens.
View Article and Find Full Text PDFJ Res Pharm Pract
August 2025
Pharmaceutical Care Administration, Armed Forces Hospital Southern Region, Khamis Mushait, Saudi Arabia.
Objective: This study evaluated pharmacists' and pharmacy technicians' knowledge, attitudes, and practices (KAPs) regarding pharmacovigilance and adverse drug reaction (ADR) reporting at a tertiary care facility in Saudi Arabia. It also sought to identify the barriers to ADR reporting and propose strategies to improve pharmacovigilance practices. This study is timely given recent initiatives by the Saudi Vision 2030 to strengthen medication safety practices nationwide.
View Article and Find Full Text PDFFront Bioinform
August 2025
Yemaachi Biotech, Accra, Ghana.
Variations in drug-metabolizing enzymes and transporters are associated with adverse drug reactions (ADRs). ADRs to cancer drugs can differ among populations owing to environmental and genetic differences. Due to limited resources and prohibitive costs associated with drug development, African countries rely on cancer drugs developed from non-African genetic backgrounds.
View Article and Find Full Text PDF